Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, NY, USA.
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, NY, USA.
Int Braz J Urol. 2021 Jul-Aug;47(4):777-783. doi: 10.1590/S1677-5538.IBJU.2020.0149.
Partial Nephrectomy is oncological safe in patients with pT3a RCC.
To compare the oncological and functional outcomes of patients with pT3a RCC scheduled for PN and RN.
We retrospectively reviewed patients with pT3a N0 M0 RCC who underwent partial or radical nephrectomy from 2005 to 2016. Perioperative characteristics, including estimated glomerular filtration rate, tumor size, pathological histology, and RENAL nephrometry score, were compared between patients scheduled for partial or radical nephrectomy. We used multivariable Cox proportional hazards regression models to compare overall survival, cancer-specific survival, and recurrence-free survival between planned procedure type.
Of the 589 patients, 369 (63%) and 220 (37%) were scheduled for radical and partial nephrectomy, respectively; 26 (12%) of the scheduled partial nephrectomy cases were intraoperatively converted to radical nephrectomy. After adjusting for tumor size and histology, there were no statistically significant differences in overall survival (hazard ratio 0.66; 95% CI, 0.38-1.13), cancer-specific survival (hazard ratio 0.53; 95% CI, 0.16-1.75), or recurrence-free survival (hazard ratio 0.66; 95% CI, 0.34-1.28) between patients scheduled for partial or radical nephrectomy. Fewer patients scheduled for partial nephrectomy had estimated glomerular filtration rate reductions 3 to 9 months after surgery than patients scheduled for radical nephrectomy.
We found no evidence that patients scheduled to undergo partial nephrectomy had poorer oncologic outcomes than patients scheduled to undergo radical nephrectomy. In select patients with pT3a renal cell carcinoma in whom partial nephrectomy is deemed feasible by the surgeon, partial nephrectomy should not be discouraged.
部分肾切除术在 pT3aRCC 患者中具有肿瘤安全性。
比较计划行部分肾切除术和根治性肾切除术的 pT3aRCC 患者的肿瘤学和功能结果。
我们回顾性分析了 2005 年至 2016 年间接受部分或根治性肾切除术的 pT3aN0M0RCC 患者。比较了计划行部分或根治性肾切除术的患者的围手术期特征,包括估算肾小球滤过率、肿瘤大小、病理组织学和 RENAL 肾切除术评分。我们使用多变量 Cox 比例风险回归模型比较了计划手术类型之间的总生存率、癌症特异性生存率和无复发生存率。
在 589 例患者中,369 例(63%)和 220 例(37%)分别计划行根治性和部分肾切除术;26 例(12%)计划行部分肾切除术的病例术中改为根治性肾切除术。调整肿瘤大小和组织学后,计划行部分肾切除术和根治性肾切除术的患者在总生存率(风险比 0.66;95%置信区间,0.38-1.13)、癌症特异性生存率(风险比 0.53;95%置信区间,0.16-1.75)或无复发生存率(风险比 0.66;95%置信区间,0.34-1.28)方面无统计学差异。计划行部分肾切除术的患者术后 3 至 9 个月估算肾小球滤过率下降的比例低于计划行根治性肾切除术的患者。
我们没有发现证据表明计划行部分肾切除术的患者的肿瘤学结果比计划行根治性肾切除术的患者差。在部分外科医生认为可行的 pT3a 肾细胞癌的特定患者中,不应劝阻部分肾切除术。